| pubmed-article:9759934 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C1547239 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C1517499 | lld:lifeskim |
| pubmed-article:9759934 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9759934 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:9759934 | pubmed:dateCreated | 1998-12-11 | lld:pubmed |
| pubmed-article:9759934 | pubmed:abstractText | Mutations of the tumor suppressor gene p53 are the most common genetic alterations observed in human cancer. Loss of wild-type p53 function impairs cell cycle arrest as well as repair mechanisms involved in response to DNA damage. Further, apoptotic pathways as induced by radio- or chemotherapy are also abrogated. Gene transfer of wild-type p53 was shown to reverse these deficiencies and to induce apoptosis in vitro and in preclinical in vivo tumor models. A phase I dose escalation study of a single intratumoral injection of a replication-defective adenoviral expression vector encoding wild-type p53 was carried out in patients with incurable non-small cell lung cancer. All patients enrolled had p53 protein overexpression as a marker of mutant p53 status in pretreatment tumor biopsies. Treatment was performed either by bronchoscopic intratumoral injection or by CT-guided percutaneous intratumoral injection of the vector solution. Fifteen patients were enrolled in two centers, and were treated at four different dose levels ranging from 10(7) to 10(10) PFU (7.5 x 10(9) to 7.5 x 10(12) particles). No clinically significant toxicity was observed. Successful transfer of wild-type p53 was achieved only with higher vector doses. Vector-specific wild-type p53 RNA sequences could be demonstrated in posttreatment biopsies of six patients. Transient local disease control by a single intratumoral injection of the vector solution was observed in four of those six successfully transduced patients. There was no evidence of clinical responses at untreated tumor sites. Wild-type p53 gene therapy by intratumoral injection of a replication-defective adenoviral expression vector is safe, feasible, and biologically effective in patients with advanced non-small cell lung cancer. | lld:pubmed |
| pubmed-article:9759934 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9759934 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9759934 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9759934 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9759934 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9759934 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9759934 | pubmed:issn | 1043-0342 | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:DalquenPP | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:SchulerMM | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:HuberCC | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:HerrmannRR | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:SchlegelJJ | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:SwansonSS | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:HorowitzJ AJA | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:PerruchoudA... | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:BolligerC TCT | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:KommossFF | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:KauczorH UHU | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:RochlitzCC | lld:pubmed |
| pubmed-article:9759934 | pubmed:author | pubmed-author:FritzM AMA | lld:pubmed |
| pubmed-article:9759934 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9759934 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:9759934 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:9759934 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9759934 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9759934 | pubmed:pagination | 2075-82 | lld:pubmed |
| pubmed-article:9759934 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:meshHeading | pubmed-meshheading:9759934-... | lld:pubmed |
| pubmed-article:9759934 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9759934 | pubmed:articleTitle | A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. | lld:pubmed |
| pubmed-article:9759934 | pubmed:affiliation | Department of Medicine III, Johannes Gutenberg University, Mainz, Germany. | lld:pubmed |
| pubmed-article:9759934 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9759934 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9759934 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9759934 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9759934 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9759934 | lld:pubmed |
